LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Akciju saraksts・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

3.75 -0.27

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.73

Max

3.84

Galvenie mērījumi
By Trading Economics
Ienākumi	8.3M -18M
Pārdošana	9.6M 10M
P/E Sektora vidējais	22.5 49.701
EPS	-0.1
Peļņas marža	-177.89
Darbinieki	69
EBITDA	8M -19M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+227.13% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 6. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-143M 767M
Iepriekšējā atvēršanas cena	4.02
Iepriekšējā slēgšanas cena	3.75

Ziņu noskaņojums

By Acuity

50%

155 / 345 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

0.7658 / N/A Atbalsts un pretestība

CytomX Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 22. maijs 16:33 UTC

Peļņas

Galvenie tirgus virzītāji

Webull Shares Slide on 1Q Loss, Soaring Costs

2026. g. 22. maijs 21:10 UTC

Peļņas

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

2026. g. 22. maijs 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 22. maijs 20:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 22. maijs 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 22. maijs 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 22. maijs 19:47 UTC

Peļņas

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

2026. g. 22. maijs 19:17 UTC

Tirgus saruna

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

2026. g. 22. maijs 19:10 UTC

Tirgus saruna

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

2026. g. 22. maijs 18:54 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 22. maijs 18:54 UTC

Tirgus saruna

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

2026. g. 22. maijs 18:38 UTC

Tirgus saruna

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

2026. g. 22. maijs 18:35 UTC

Iegādes, apvienošanās, pārņemšana

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

2026. g. 22. maijs 18:09 UTC

Tirgus saruna

Centralized Crypto Lending Slows in 1Q -- Market Talk

2026. g. 22. maijs 17:58 UTC

Tirgus saruna

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

2026. g. 22. maijs 17:54 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2026. g. 22. maijs 17:54 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 22. maijs 17:54 UTC

Tirgus saruna

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

2026. g. 22. maijs 17:03 UTC

Tirgus saruna

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

2026. g. 22. maijs 16:54 UTC

Tirgus saruna

Crypto Spot Volumes Fall 14% in April -- Market Talk

2026. g. 22. maijs 16:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 22. maijs 16:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 22. maijs 16:20 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 22. maijs 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 22. maijs 16:16 UTC

Tirgus saruna

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

2026. g. 22. maijs 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 22. maijs 15:55 UTC

Tirgus saruna

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

2026. g. 22. maijs 15:42 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 22. maijs 15:42 UTC

Tirgus saruna

Oil Continues as Leading Indicator for All Markets -- Market Talk

2026. g. 22. maijs 15:35 UTC

Tirgus saruna

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Salīdzinājums

Cenas izmaiņa

CytomX Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

227.13% augšup

Prognoze 12 mēnešiem

Vidējais 12.3 USD 227.13%

Augstākais 16 USD

Zemākais 6 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

10 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

0.7658 / N/AAtbalsts un pretestība

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Noskaņojums

By Acuity

155 / 345 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.